NeoImmuneTech (NIT), a clinical-stage T cell-focused biopharmaceutical company, today announced the appointment of new members of its Scientific Advisory Board.
Professor Richard Kim (Moffitt Cancer Center, Florida, US), Associate Professor Young Kwang Chae (Northwestern University Feinberg School of Medicine, Illinois, US), Associate Professor Hyunseok Kang (University of California, US) and Doctor Keith Watson (Owner & Managing Director, KRW BioReg Solutions, UK) are joining Professor Ahmed Rafi on the SAB.
Dr. Se Hwan Yang, Ph.D., President and Chief Executive Officer of NeoImmuneTech said: “We are very pleased to announce the composition of our renewed Scientific Advisory Board, which reflects the company’s move into a second exciting phase of its development. NeoImmuneTech is now preparing accelerated approval and entering the later phases of clinical trials of our drug candidate NT-I7. We need solid expertise from clinical experts who work closely in clinical practice and have a strong expertise of regulatory pathways”.
The role of the Scientific Advisory Board is to advise NIT on its clinical development plan and registration strategies with the currently explored indications of NT-I7 (efineptakin alfa) (rhIL-7-hyFc) and to make recommendations on future developments of long-acting human IL-7.
Dr. Keith Watson is a quality and regulatory expert who served as a Senior biological quality assessor at the MHRA, UK as well as being a regular participant and contributor to the biologics working party (BWP) and member of various CHMP scientific guideline drafting groups at the EMA . Through his long career spanning manufacturing, development, regulatory affairs and policy within CMDO, CRO and the Biotech industry including Lonza, Parexel, Abbvie and Celltrion, Dr. Watson has developed a deep knowledge and expertise of the regulatory approval processes, more specifically with the EMA in Europe. Dr. Watson has a Ph.D. in biochemistry from the Imperial College of London (UK).
Dr. Richard Kim is a Service Chief of Medical Gastrointestinal Oncology and Senior Member in the Gastrointestinal Oncology Department at Moffitt Cancer Center (Florida, US). He is a Professor of Oncology at the University of South Florida College of Medicine. Dr. Kim’s clinical and research interests focus on gastrointestinal tumors, in particular hepatobiliary and colon cancer. He is a principal investigator in multiple investigator-initiated and pharmaceutical phase 1, 2, 3 trials using immunotherapy and novel targeted agents. He is the principal investigator of the phase 1-2 study NIT-110 that explores the safety and efficacy of NT-I7 in combination with pembrolizumab in multiple solid tumors.
Dr. Hyunseok Kang is Associate Professor of Clinical Medicine at the University of California, San Francisco. As a specialist in head and neck cancers, his expertise encompasses conventional chemotherapy, targeted and immunotherapy. In his research, Dr. Kang studies how to improve the efficacy of immune checkpoint inhibitors with combination approaches. He is the principal investigator of the phase 1 study NIT-115 evaluating NT-I7 in head and neck squamous cell carcinomas. Dr. Kang earned his medical degree at Yonsei University College of Medicine in Seoul (Korea).
After graduating from the Seoul National University (Korea) as a medical doctor, Dr. Young Kwang Chae pursued his scholarship at the Johns Hopkins University where he passed an MBA and MPH. He is an Associate Professor at the Northwestern University Feinberg School of Medicine (Illinois, US). His clinical and research interests focus on breast cancer, gastrointestinal cancer, lung cancer, mesothelioma and thymic cancer. He has led several research projects in Immuno-oncology.
Dr. Rafi Ahmed, Ph.D., is Professor of Microbiology and Immunology at Emory University School of Medicine, where he is also the director of the Emory Vaccine Center. His work has uncovered the primary role of the PD-1 inhibitory receptor in the promotion of T cell dysfunction during chronic infection which directly led to the successful use of PD-1 checkpoint blockade therapy in cancer patients. He has been a member of the Scientific Advisory Board for the last three years, and he will continue to collaborate with NIT.
Copyright © Korea IT Times